热门资讯> 正文
周日报道称，细胞激素在2025年欧洲癌症学会大会上提交的多项临床试验中强调了阿非康坦一致的长期安全性和有效性
2025-09-02 15:38
- Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology
- New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%, Consistent with Expected Rates in Prediction Model of Patients with HCM; Simultaneous Publication in Heart Rhythm
- Longer-Term Data Presented Consistent with Previously Reported Safety Profile of Aficamten
- Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:30 AM Eastern Time
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
